Agilent Technologies (A) reported a 35% jump in earnings for the third quarter as the global pharma and chemical & energy end markets drove the top-line higher. The scientific instrument maker raised the outlook for the full year 2018 after the bottom line exceeded the Street’s expectations.
Net income for the quarter soared 35% to $236 million or $0.73 per share. Adjusted earnings increased by 14% to $0.67 per share.
Revenue grew by 8% year-over-year to $1.2 billion helped by the strength across its business segments.
Looking ahead into the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.26 billion, and non-GAAP earnings in the range of $0.72 to $0.74 per share.
For the fiscal year 2018, Agilent lifted revenue outlook to the range of $4.86 billion to $4.88 billion from the previous estimate of $4.85 billion to $4.87 billion. Adjusted earnings guidance was lifted up to the range of $2.69 to $2.71 per share from prior forecast of $2.63 to $2.67 per share.
Revenue from Agilent’s Life Sciences and Applied Markets Group for the third quarter rose by 6% year-over-year helped by the strength in the chemical & energy and pharma end markets. Revenue from Agilent CrossLab Group grew 10% as both services and consumables saw strong growth across all end markets and geographies. Revenue from Agilent’s Diagnostics and Genomics Group increased 9% driven by the strength in genomics and China.
During the third quarter of 2018, the company repurchased $243 million in shares, paid $48 million in dividends, and invested $430 million in mergers and acquisitions.
As of July 31, 2018, Agilent has spent more cash in the daily running of the business as the balance sheet showed a 20% dip in cash and cash equivalent from October 31, 2017. Long-term investments have fallen by 49%, while goodwill and other intangible assets rose by 16%.
The company had paid off all of the short-term debt and also reduced long-term debt by 0.1%. An increase in accumulated deficit has dragged total equity lower by 5.5%.
Shares of Agilent ended Tuesday’s regular trading up 1.23% at $66.75 on the NYSE. The stock has fallen more than 3% for the past three months, while it has risen by more than 11% for the past year.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company